Evaluating or Ready to Engage an Industry Leading Preclinical CRO? Connect with T3 Labs at TCT 2018, Booth 334!

The Transcatheter Cardiovascular Therapeutics (TCT) meeting is the world’s largest educational meeting specializing in interventional cardiovascular medicine. This year, it will take place on September 21-25, 2018 in San Diego, California.

GCMI and T3 Labs will be attending as an exhibitor at TCT again this year. Our booth number is 334.  We’re excited to spend this time discussing the most recent developments in the cardiovascular field, as well as our experience in delivering high value preclinical testing and training for cardiothoracic devices.

“At T3 Labs they have the perfect setup for what we needed. From the cath lab to fluoroscopy to large animal proficiency, not to mention years of expertise specific to cardiology.” – Dr. Rebecca Levit – Chief Scientific Officer of CorAmi Therapeutics. Read more.

Follow T3 Labs on LinkedIn and Twitter.

T3 is an industry-leading preclinical CRO that performs transcatheter cardiovascular device testing and training, amongst many other therapeutic area T3 Labs’ GLP preclinical program for transcatheter interventional cardiovascular devices includes experience in models of ischemia, transcatheter/interventional implants, telemetry, vascular access etc. Our preclinical CRO employs the most appropriate, efficient model and has all the needed equipment.

We look forward to connecting with sponsors, as well as regulatory officials, to further understand what they look for in transcatheter innovations and how we can better design preclinical studies for transcatheter devices.

Make sure to find us at TCT 2018 to discuss any transcatheter preclinical medical device testing needs you may have and the guidance that GCMI can provide to take your idea from concept to commercialization. Hopefully our new branding and booth will make us hard to miss! If you’re the type that likes to get your meetings lined up early, contact Deepal Panchal or contact us to schedule an on-site meeting at TCT 2018!

Related:

JACC-CI study & ACC Distinguished Award winner evidence T3 leads the way in preclinical cardiovascular research